Silence Seeks Share Of Alnylam RNAi Success In Legal Action

 
• By Kevin Grogan

The UK firm believes its siRNA stabilisation chemistryis represented in several late-stage RNAi studies and that market leader Alnylam requires a license that could have a material impact on Silence's market capitalization.

DNA_1200
The promise of RNAi is close to providing a marketed product • Source: Shutterstock

More from Business

More from Scrip